Tenofovir Amibufenamide
Chronic Hepatitis B Virus Infection
Explore 11 assets in Chronic Hepatitis B Virus Infection →Floatz Rating
CCC50/100
Confidence
Indicative
Sponsor
Ningbo No.2 Hospital
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
35Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07553767CT.gov Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection | — | Not Yet Recruiting | — | — | — |
NCT07295873CT.gov Drug-Drug Interaction Study Between Hydronidone and Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide, and Tenofovir Amibufenamide | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chronic Hepatitis B Virus Infection
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tenofovir Amibufenamide (this asset) | Ningbo No.2 Hospital | P1 | CCC · 50 |
| Lamivudine | Yonsei University | P4 | BBB |
| Entecavir | Beijing Continent Pharmaceutical Co, Ltd. | P4 | BBB |
| Telbivudine | The Fifth People's Hospital of Suzhou | P4 | BBB |
| Tenofovir Alafenamide | Ningbo No.2 Hospital | P4 | BB |
| Pegyinterferon-Alfa-2A | Huashan Hospital | P4 | BB |
| Adefovir Dipivoxil | Asian-Pacific Alliance of Liver Disease, Beijing | P4 | BB |
| Tenofovir Disoproxil Fumarate | Ningbo No.2 Hospital | P4 | BB |
| Hydronidone | Beijing Continent Pharmaceutical Co, Ltd. | P3 | BB |
+17 more in the Chronic Hepatitis B Virus Infection cohort
Other indications for Tenofovir Amibufenamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hepatocellular Carcinoma | — | Early P1 | C · 34 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tenofovir Amibufenamide in Chronic Hepatitis B Virus Infection. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tenofovir-amibufenamide-chronic-hepatitis-b-virus-infection
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →